A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss

The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) has dramatically improved over the last decade; however, patients with visceral metastases are still faced with poor outcomes. Phosphatase and tensin homolog (PTEN) loss is observed in 40%–60% of mCRPC patients and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Myint, Zin W., Allison, Derek B., Ellis, Carleton S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495426/
https://www.ncbi.nlm.nih.gov/pubmed/34631559
http://dx.doi.org/10.3389/fonc.2021.731002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495426/
https://www.ncbi.nlm.nih.gov/pubmed/34631559
http://dx.doi.org/10.3389/fonc.2021.731002

Ejemplares similares